zolbetuximab + nab-paclitaxel + gemcitabine
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Trial Timeline
Mar 15, 2019 → Aug 31, 2026
NCT ID
NCT03816163About zolbetuximab + nab-paclitaxel + gemcitabine
zolbetuximab + nab-paclitaxel + gemcitabine is a phase 2 stage product being developed by Astellas Pharma for Pancreatic Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03816163. Target conditions include Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Cancer were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03816163 | Phase 2 | Active |
Competing Products
20 competing products in Pancreatic Cancer